PersonExecutiveScientist
Ramon Salsas Escat
Ramon Salsas Escat is the Chief Business Officer of GEMMA Biotherapeutics (GemmaBio), the Philadelphia gene-therapy company spun out of Jim Wilson's lab to widen global access to AAV therapies for rare inherited diseases. A chemist by training who earned a PhD in computational and systems biology at MIT and an MBA at IESE, Salsas has led or co-led more than 20 transactions across AAV gene therapies, CNS disorders, oncology and manufacturing platforms, with cumulative deal value north of $4 billion in upfront payments and milestones. He helped build the business engine at Penn's Gene Therapy Program, served as SVP of Business Development at G2 Bio, and now runs business development, alliance management, legal and IP at GemmaBio, where he played a pivotal role in the company's founding and its $34 million seed round.
gene therapyaavrare diseasebiotechbusiness developmentchief business officer
